CDEK
← All drugs Report issue

tivozanib

Trade name: Fotivda

Small moleculeapproved

Approved

Mar 10, 2021

Tivozanib, sold under the brand name Fotivda, is a medication used for the treatment of advanced renal cell carcinoma. It is an oral VEGF receptor tyrosine kinase inhibitor. — Wikipedia

Clinical trial activity

46 trials · 30 clinical orgs · 1 marketing orgs

Phase 1
19
Phase 2
32
Phase 3
7
Phase 4
0

Earliest trial started Sep 1, 2001 (NCT00039780)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2007

    AVEO Pharmaceuticals — Earliest Phase 1 Sponsor(trial)

2020s

  1. Mar 10, 2021

    AVEO Pharmaceuticals — Earliest FDA Approval

  2. Mar 10, 2021

    AVEO Pharmaceuticals — Marketing Organization

  3. Mar 10, 2021

    AVEO Pharmaceuticals — NDA Secondary Org

  4. Mar 10, 2021

    AVEO Pharmaceuticals — NDA Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedMar 10, 2021

Chemistry & pharmacology

Loading structure…

SMILES

O=S(=O)(O)CCSSCCS(=O)(=O)O
Mol. weight
282.39 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2,2'-dithiodiethanesulfonic acid
  • 2,2'-dithiodiethanesulfonic acid, ammonium salt
  • 2,2'-dithiodiethanesulfonic acid, disodium salt
  • asp-4130
  • asp-4130
  • av 951
  • av-951
  • av-951
  • av-951
  • av951 cpd
  • bnp7787
  • bnp7787
  • bnp7787
  • dimesna
  • dimesna
  • dimesna
  • dimesna
  • dimesna sodium
  • disodium 2,2'-dithio-bis-ethane sulfonate
  • ethanesulfonic acid, 2,2'-dithiobis-
  • kil8951
  • kil8951
  • kil-8951
  • kil-8951
  • krn951
  • krn951
  • krn951
  • krn 951
  • krn-951
  • krn-951
  • krn-951
  • tavocept
  • tavocept
  • tavocept
  • tivozanib
  • tivozanib
  • tivozanib
  • tivozanib
  • tivozanib
  • tivozanib
  • tivozanib hcl
  • tivozanib hcl
  • tivozanib hydrochloride
  • tivozanib hydrochloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07218692Phase 2Aug 11, 2026City of Hope National Medical Center, National Cancer Institute (NCI)
NCT06661720Phase 3Nov 7, 2024National Cancer Institute (NCI)
NCT06053658Phase 2Jan 31, 2024AVEO Pharmaceuticals, University of Texas at Houston
NCT06116890Phase 2Nov 30, 2023Kyowa Hakko Kirin
NCT06116916Phase 2Nov 30, 2023Kyowa Hakko Kirin
NCT05456256Phase 2Aug 12, 2022Lantern Pharma Inc.
NCT05000294Phase 1/Phase 2 (Phase 2)Nov 3, 2021AVEO Pharmaceuticals, Genentech, University of Florida
NCT04987203Phase 3Sep 9, 2021AVEO Pharmaceuticals, Bristol-Myers Squibb, Parexel
NCT04645160Phase 1/Phase 2 (Phase 2)Jan 8, 2021National Cancer Institute (NCI)
NCT04594681Phase 1Sep 16, 2020Kyowa Hakko Kirin
NCT03970616Phase 1/Phase 2 (Phase 2)Aug 31, 2019AstraZeneca, AVEO Pharmaceuticals
NCT03136627Phase 1/Phase 2 (Phase 2)Mar 22, 2017AVEO Pharmaceuticals, Bristol-Myers Squibb, Institut Gustave Roussy
NCT02627963Phase 3Apr 1, 2016AVEO Pharmaceuticals
NCT01972516Phase 2Nov 1, 2013AVEO Pharmaceuticals, Harvard University, National Comprehensive Cancer Network
NCT01728181Phase 1/Phase 2 (Phase 2)Nov 1, 2013University of Utah
NCT01835223Phase 1/Phase 2 (Phase 2)Jul 11, 2013AVEO Pharmaceuticals, National Cancer Institute (NCI), National Comprehensive Cancer Network, State University of New York, Buffalo
NCT01846871Phase 2Jun 1, 2013Harvard University, National Comprehensive Cancer Network
NCT01834183Phase 2Jun 1, 2013Harvard University
NCT01885949Phase 2Jun 1, 2013Harvard University, National Comprehensive Cancer Network
NCT01853644Phase 2May 1, 2013National Comprehensive Cancer Network, Northwestern University
Showing 20 of 46 trials
Page 1 / 3

Organizations

Research & Development (30)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AVEO PharmaceuticalsFor profit302242007
Harvard UniversityAcademic/Hospital6522009
National Cancer Institute (NCI)Government6332004
National Comprehensive Cancer NetworkAcademic/Hospital5012013
Cornell UniversityAcademic/Hospital4022009
Kyowa Hakko KirinFor profit4422009
AstellasFor profit2012012
BioNumerik Pharmaceuticals, Inc.For profit2212001
Bristol-Myers SquibbFor profit2022017
Northwestern UniversityAcademic/Hospital2212013
State University of New York, BuffaloAcademic/Hospital2222013
AstraZenecaFor profit1012019
City of Hope National Medical CenterAcademic/Hospital1112026
CovanceFor profit1012011
Emory UniversityAcademic/Hospital1112013
Erasmus University RotterdamAcademic/Hospital1012008
GenentechFor profit1012021
Georgetown UniversityAcademic/Hospital1012009
Institut Gustave RoussyAcademic/Hospital1012017
Lantern Pharma Inc.For profit1112022
30 organizations
Page 1 / 2

Marketing (3)

OrganizationOrg typeRelationshipDate
AVEO PharmaceuticalsFor profitMKTGMar 10, 2021
AVEO PharmaceuticalsFor profitNDA2Mar 10, 2021
AVEO PharmaceuticalsFor profitNDAMar 10, 2021